Plasminogen activator inhibitor type 1: Physiology and role in renal pathophysiology;L'inhibiteur de type 1 des activateurs du plasminogène: Physiologie et rôle en physiopathologie rénale

Nephrologie

Volumn 22, Issue 1, 2001, Pages 5-13

  Rerolle, J Ph ^a   Vigneau, C ^a   Hertig, A ^a   Berrou, J ^a   Rondeau, E ^a  

^a HÔPITAL TENON   (France)

Author keywords

Cellular mobility; Fibrosis; Kidney; PAI 1

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL MOTILITY; FIBRINOLYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FIBROSIS; LUNG FIBROSIS; NIDATION; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOEMBOLISM; TUMOR GROWTH;

ALDOSTERONE; FIBRINOLYSIS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035097120     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Absence of host plasminogen activator inhibitor 1 prevent cancer invasion and vascularization
2. Expression of plasminogen activator inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rats
3. Vascular development and disorders: Molecular analysis and pathhogenic insights
4. The renal plasminogen activating system
5. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectine
6. Characterisation of a plasminogen activator and its inhibitor in human mesangial cells
7. Localization of fibrinolytic activity in the kidney and urinary tract of rats and rabbits
8. Of mice and men the function of plasminogen activator inhibitors (PAIs) in vivo
9. The plasminogen activator/plasmin system
10. A surprising new protein superfamilly containing ovalbumin, antithrombin III and alpha 1-proteinase inhibitor
11. Plasminogen activator inhibitors
12. Quantification and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells
13. Plasminogen activator inhibitors - A review
14. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
15. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells
16. Structure of the human plasminogen activator inhibitor 1 gene: Nonrandom distribution of introns
17. Interleukin 1β up-regulates the plasminogen activator/plasmin system in human mesangial cells
18. Effect of TGF-β1 and TNF-α on the plasminogen system of rat proximal tubular epithelial cells
19. Direct binding of smad 3 and smad 4 to critical TGF-β-inducible elements in the promoter of the human plasminogen activator inhibitor type-1 gene
20. Thrombin regulates components of the fibrinolytic system in human mesangial cells
21. The two allele sequences of a common polymorphism in the promoter of the plasmlnogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells
22. Plasminogen activator inhibitor in plasma: Risk factor for reccurent myocardial infarction
23. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
24. Plasmmnogen activators, tissue degradation, and cancer
25. Urokinase and urokinase receptor: A paracrine autocrine system regulating cell migration and invasiveness
26. Developmental expression of the syndecans: Possible function and regulation
27. Contact and adhesive specificities in the associations, migrations and targetting of cells and axons
28. Cell adhesion: The molecular basis of tissue architecture and morphogenesis
29. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
30. Biology and biochemistry of proteinases in tumor invasion
31. Identification of the urokinase receptor as an adhesion receptor for vitronectin
32. Purification and characterisation of a plasminogen activator inhibitor 1 binding protein from human plasma: Identification as a multimeric form of S protein (vitronectin)
33. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in nodenegative breast cancer
34. Biological effects of the disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 genes in mice
35. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
36. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis
37. Bleeding diathesis due to decreased functionnal activity of type 1 plasminogen activator inhibitor
38. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or reccurent deep vein thrombosis
39. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice
40. Fibrinolysis and atherosclerosis: An uptade
41. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
42. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury
43. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis
44. Plasminogen activator inhibitor-1 in renal fibrin deposits of human nephropathies
45. Glomerular hemostasis in normal and pathologic conditions
46. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lake or overexpress the murine plasminogen activator inhibitor-1 gene
47. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system
48. Renal expression of genes that promote interstitial inflammation and fibrosis in rat with protein-overload proteinuria
49. Induction of activator inhibitor type 1 in murine lupus-like glomerulonephritis
50. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney
51. Plasminogen activator inhibitor-1 deposition in the extracellular matrix of culture human mesangial cells
52. Réduction de la libération du TNF-alpha et effets cliniques de la première injection d'OKT3
53. LPS induces major changes in the extracellular proteolytic balance in the murine kidney
54. Modulation of plasminogen activator inhibitor type-1 in vivo: A new mechanism for the antifibrotic effect of renin-angiotensin inhibition
55. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis
56. Expression of transforming growth factor-β isoforms in human glomerular diseases
57. Pathophysiology of progressive nephropathies
58. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice
59. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
60. Histological findings in early routine biopsies of stable allograft recipients
61. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions
62. Tissue factor in normal and transplanted human kidneys
63. Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts
64. Expression of type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure
65. Activation of the serine proteinase system in chronic kidney rejection
66. Cytokines in kidney disease: The role of transforming growth factor-beta
67. Transforming growth factor-β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans
68. Regulation of cell adhesion receptors by transforming growth factor-β
69. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor
70. Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit
71. 1
72. Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy
73. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: Induction by transforming g rowth factor-β, lipopolysaccharide and tumor necrosis factor-α
74. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator-1 synthesis in vascular smooth muscle cells
75. Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts
76. Specific induction of secreted protein by transforming growth factor-β and 12-O-tetradecanoylphorbol-13-acetate
77. Multiple transforming growth factor-β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 in Hep G2 cells
78. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo
79. Overexpression of glutamine fructose-6-phosphate amidotransferase (GFAT) activates the the plasminogen activator inhibitor type-1 (PAI-1)
80. Angiotensin II stimumates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells
81. Induction of platelet-derived growth factor chain-A and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells
82. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy
83. Effect of angiotensin II on the expression of plasminogen activator inhibitor (PAI-1) in rat mesangial cells
84. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
85. Angiotensin II regulates expression of plasminogen activator inhibitor-1 in cultured endothelial cells
86. Mesangial matrix modulation and glomerulosclerosis
87. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
88. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in neointima of balloon-injured rat aorta
89. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
90. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
91. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
92. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure